References
- Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
- European Study Group on interferon beta-1b in secondary progressive MSPlacebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MSLancet19983529139149114979820296
- DurelliLVerdunEBarberoPIndependent Comparison of Interferon (INCOMIN) Trial Study GroupEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet200235993161453146011988242
- PanitchHMillerAPatyDWeinshenkerBNorth American Study Group on Interferon beta-1b in Secondary Progressive MSInterferon beta-1b in secondary progressive MS: results from a 3-year controlled studyNeurology200463101788179515557491
- KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology20066771242124916914693
- O’ConnorPFilippiMArnasonBBEYOND Study Group250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol200981088989719729344
- HartungHPEarly treatment and dose optimisation BENEFIT and BEYONDJ Neurol2005252Suppl 3iii44iii5016170501
- PaolicelliDDirenzoVTrojanoMReview of interferon beta-1b in the treatment of early and relapsing multiple sclerosisBiologics2009336937619707422
- GoodinDSRederATEbersGCSurvival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trialNeurology201278171315132222496198
- KozubskiWAutoinjector improves injection-related tolerability issues in patients with multiple sclerosis – exploring the new ExtaviJect™ 30G system for the injection of interferon beta-1bEur Neurol Rev2010527781
- GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler201218793294622249762
- BalakDMHengstmanGJÇakmakAThioHBCutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewMult Scler201218121705171722371220
- BrochetBLemaireGBeddiafAet l’Epicure Study GroupReduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devicesRev Neurol (Paris)20061626–7735740 French16840982
- PozzilliCSchweikertBEcariUOentrichWBetaPlus Study groupSupportive strategies to improve adherence to IFN β-1b in multiple sclerosis – results of the βPlus observational cohort studyJ Neurol Sci20113071–212012621636099
- BoeruGMilanovIDe RobertisFExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European studyMed Devices (Auckl)In press2013